Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2024-04-23 Major Shareholding Noti…
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document is titled "Storaktionærmeddelelse" (Major Shareholder Announcement) and explicitly states that DMZ Holding ApS has increased its ownership stake to over 5% in Pharma Equity Group A/S, referencing the Danish Capital Markets Act (§ 38). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing thresholds. The appropriate code is MRQ.
2024-04-23 Danish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "Major shareholder announcement" and details that DMZ Holding ApS has acquired shares, increasing their ownership stake to over 5% in Pharma Equity Group A/S, citing compliance with section 38 of the Capital Markets Act. This directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The document is short and appears to be a regulatory disclosure rather than a comprehensive report.
2024-04-23 English
Major shareholder announcement - Pharma Equity Group A/S
Major Shareholding Notification Classification · 100% confidence The document is a 'Storaktionærmeddelelse' (Major Shareholder Notification) from Pharma Equity Group A/S. It explicitly states that DMZ Holding ApS has acquired shares, resulting in their ownership exceeding the 5% threshold. This falls directly under the definition of a Major Shareholding Notification (MRQ).
2024-04-23 Danish
Major shareholder announcement - Pharma Equity Group A/S
Major Shareholding Notification Classification · 100% confidence The document is titled 'Major shareholder announcement' and explicitly states that Pharma Equity Group A/S has received a notification regarding a change in ownership stake (DMZ Holding ApS increasing stake to over 5%). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2024-04-23 English
Regulatory Filings 2024
Regulatory Filings Classification · 98% confidence The document is a Company Announcement (No. 11) dated April 5, 2024, reporting highly positive final results from a Phase-2 clinical trial (MEFO trial) for a drug candidate (RNX-051) by a subsidiary (Reponex Pharmaceuticals A/S). It details the protocol, statistical results (p-values, fold reductions, cell densities), and conclusions regarding the drug's efficacy against colon cancer precursors and cancer. This content strongly aligns with an announcement of clinical trial results, which is typically released as an Earnings Release (ER) if it's a key highlight, or sometimes as a Regulatory Filing (RNS) if it's purely scientific news not tied to a standard quarterly report. Since it announces specific, positive financial/operational milestones (clinical trial success) that drive investor interest, it functions as an Earnings Release, even though it's not explicitly labeled as a quarterly earnings report. It is a primary announcement of operational success, not a full report (10-K, IR) or a transcript (CT). Given the nature of reporting key operational/clinical milestones, ER is the most appropriate fit among the options provided for a standalone, positive operational update.
2024-04-05 English
Earnings Release 2024
Earnings Release Classification · 99% confidence The document is a press release dated April 5, 2024, titled "Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, rapporterer meget positive slutresultater fra det klinisk fase-2 studie med selskabets patenterede lægemiddelkandidat RNX-051." It details the positive final results from a Phase 2 clinical study (MEFO study) concerning a drug candidate (RNX-051) for colorectal cancer/polyps, including protocol, detailed results (biomass reduction, immune cell density, bacterial composition changes), and conclusions. This content strongly aligns with an Earnings Release (ER) or a specific announcement of clinical trial results, which often precedes or is part of an Earnings Release, especially when it's a major operational update. Since it focuses purely on the results of a specific study and its implications, it is best classified as an Earnings Release (ER) as it communicates key financial/operational performance milestones, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format and focus on results announcement, ER is more appropriate than the general Regulatory Filing (RNS) or the comprehensive Interim Report (IR). It is not a transcript (CT), a formal annual report (10-K), or a management discussion (MDA) of full financials, but rather the announcement of a key operational milestone. Given the options, 'ER' (Earnings Release) is the closest fit for a press release announcing significant operational/clinical trial results. Q2 2024
2024-04-05 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.